Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinico-laboratory pertinences and management of relapsed and refractory.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology - 1 Jan 2000

Musteata Vasile

Abstract excerpt

PURPOSE: The purpose of this study was to assess the biological significance of lactate dehydrogenase (LDH), T315I mutation and treatment options in newly diagnosed and relapsed patients with chronic myeloid leukemia (CML). METHODS: Our clinical-analytical and descriptive study enrolled 27 patients with different phases of CML, who were followed up and treated at the Institute of Oncology between 1995-2020....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Drug Resistance, Neoplasm
Share to Fusion Proteins, bcr-abl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to L-Lactate Dehydrogenase

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation

Share to Recurrence

Share to Young Adult

Source

Identifiers

PMID: 34268985

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinico-laboratory pertinences and management of relapsed and refractory.PMID 34268985Read ↗

A review of the European LeukemiaNet recommendations for the management of CML.Semantic proximity Read ↗

[Recommendations from the GBMHM and the Fi-LMC for the diagnosis and management of chronic myeloid leukemia].Semantic proximity Read ↗

Clinical characteristics, disease evolution and survival in patients with chronic myeloid leukemia, BCR-ABL1 (+) and T315I mutation.Semantic proximity Read ↗

Treatment and molecular monitoring update in chronic myeloid leukemia management.Semantic proximity Read ↗

From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care.Semantic proximity Read ↗

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.Semantic proximity Read ↗

Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia.Semantic proximity Read ↗

Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories.Semantic proximity Read ↗

Practical Laboratory Tools for Monitoring of BCR-ABL1 Transcripts and Tyrosine Kinase (TK) Domain Mutations in Chronic Myeloid Leukemia Patients Undergoing TK Inhibitor Therapy: A Single-Center Experience in Thailand.Semantic proximity Read ↗

Molecular monitoring in CML: how deep? How often? How should it influence therapy?Semantic proximity Read ↗

Update on the use of hydroxyurea for the early management of chronic-phase- chronic myeloid leukemia: data from a real-world cohortSemantic proximity Read ↗

Prolonged indolent clinical course in a high-risk chronic phase-CML patient without cytogenetic or molecular response: a case challenging established response paradigmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.